South Korea · Delayed Price · Currency is KRW Cell Biotech Statistics
Total Valuation
Cell Biotech has a market cap or net worth of KRW 102.11 billion. The enterprise value is 5.89 billion.
| Market Cap | 102.11B |
| Enterprise Value | 5.89B |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Cell Biotech has 6.84 million shares outstanding. The number of shares has increased by 0.06% in one year.
| Current Share Class | 6.84M |
| Shares Outstanding | 6.84M |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 35.31% |
| Owned by Institutions (%) | 0.11% |
| Float | 4.43M |
Valuation Ratios
The trailing PE ratio is 6.08.
| PE Ratio | 6.08 |
| Forward PE | n/a |
| PS Ratio | 1.69 |
| PB Ratio | 0.75 |
| P/TBV Ratio | 0.75 |
| P/FCF Ratio | 9.43 |
| P/OCF Ratio | 5.65 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 0.43, with an EV/FCF ratio of 0.54.
| EV / Earnings | 0.35 |
| EV / Sales | 0.10 |
| EV / EBITDA | 0.43 |
| EV / EBIT | 0.58 |
| EV / FCF | 0.54 |
Financial Position
The company has a current ratio of 13.53, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.53 |
| Quick Ratio | 12.70 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 507.95 |
Financial Efficiency
Return on equity (ROE) is 12.91% and return on invested capital (ROIC) is 21.81%.
| Return on Equity (ROE) | 12.91% |
| Return on Assets (ROA) | 4.60% |
| Return on Invested Capital (ROIC) | 21.81% |
| Return on Capital Employed (ROCE) | 7.38% |
| Weighted Average Cost of Capital (WACC) | 6.82% |
| Revenue Per Employee | 598.01M |
| Profits Per Employee | 166.34M |
| Employee Count | 101 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 3.17 |
Taxes
In the past 12 months, Cell Biotech has paid 2.83 billion in taxes.
| Income Tax | 2.83B |
| Effective Tax Rate | 14.42% |
Stock Price Statistics
The stock price has increased by +15.84% in the last 52 weeks. The beta is 0.47, so Cell Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | +15.84% |
| 50-Day Moving Average | 15,465.60 |
| 200-Day Moving Average | 14,958.55 |
| Relative Strength Index (RSI) | 37.12 |
| Average Volume (20 Days) | 7,133 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cell Biotech had revenue of KRW 60.40 billion and earned 16.80 billion in profits. Earnings per share was 2,454.45.
| Revenue | 60.40B |
| Gross Profit | 43.68B |
| Operating Income | 10.10B |
| Pretax Income | 19.63B |
| Net Income | 16.80B |
| EBITDA | 13.69B |
| EBIT | 10.10B |
| Earnings Per Share (EPS) | 2,454.45 |
Balance Sheet
The company has 96.38 billion in cash and 158.86 million in debt, with a net cash position of 96.22 billion or 14,059.95 per share.
| Cash & Cash Equivalents | 96.38B |
| Total Debt | 158.86M |
| Net Cash | 96.22B |
| Net Cash Per Share | 14,059.95 |
| Equity (Book Value) | 136.74B |
| Book Value Per Share | 19,980.22 |
| Working Capital | 101.65B |
Cash Flow
In the last 12 months, operating cash flow was 18.08 billion and capital expenditures -7.25 billion, giving a free cash flow of 10.83 billion.
| Operating Cash Flow | 18.08B |
| Capital Expenditures | -7.25B |
| Depreciation & Amortization | 3.60B |
| Net Borrowing | -617.68M |
| Free Cash Flow | 10.83B |
| FCF Per Share | 1,582.19 |
Margins
Gross margin is 72.32%, with operating and profit margins of 16.72% and 27.82%.
| Gross Margin | 72.32% |
| Operating Margin | 16.72% |
| Pretax Margin | 32.50% |
| Profit Margin | 27.82% |
| EBITDA Margin | 22.67% |
| EBIT Margin | 16.72% |
| FCF Margin | 17.93% |
Dividends & Yields
This stock pays an annual dividend of 600.00, which amounts to a dividend yield of 4.02%.
| Dividend Per Share | 600.00 |
| Dividend Yield | 4.02% |
| Dividend Growth (YoY) | 33.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 24.44% |
| FCF Payout Ratio | 37.92% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 3.96% |
| Earnings Yield | 16.45% |
| FCF Yield | 10.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cell Biotech has an Altman Z-Score of 9.92 and a Piotroski F-Score of 6.
| Altman Z-Score | 9.92 |
| Piotroski F-Score | 6 |